Skip to content

Glaukos GKOS Available for sale investments

Available for sale investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's available for sale investments?
Glaukos (GKOS) reported available for sale investments of $172.44M in Q1 2026.
How has Glaukos's available for sale investments changed year-over-year?
Glaukos's available for sale investments decreased by 6.5% year-over-year, from $184.44M to $172.44M.
What is the long-term trend for Glaukos's available for sale investments?
Over 5 years (2020 to 2025), Glaukos's available for sale investments has grown at a -9.4% compound annual growth rate (CAGR), from $307.77M to $187.95M.